ALNY Alnylam Pharmaceuticalsdata gap · 17% coveragelimited data
Health Care · Pharmaceutical Preparations · close $231.83 (2026-10-16) · latest quarter in EDGAR: 2026-06-30
Alnylam Pharmaceuticals (ALNY) has a ThetaGrade House Rating of 52/100 (grade C), ranking #23 of 150 in Health Care. Only 2 pillars have usable data (balance sheet 57, cash flow 44). Data gap: 11 factors without usable data, so 17% of the method weight is covered. TTM revenue growth is — and operating margin —.
Data as of .
Data gap
No usable data for: Consensus score (1–5), 90-day net rating shift, Revenue growth YoY (TTM), EPS growth YoY (TTM), Revenue acceleration, Operating margin, 4Q gross-margin change, Net debt / EBITDA, Interest coverage, P/E (inverted), EV/Sales (inverted). Data gap: no usable data for this factor, so it is left out and its weight is shared among the factors that do have data (no value is imputed). 17% of the full method weight is backed by data.
- Revenue: fewer than 4 contiguous quarters - TTM metrics are data gaps
Analyst sentiment
weight 7.5% · no data · —| Consensus score (1–5) (0.0%)data gap | derived | — |
| 90-day net rating shift (0.0%)data gap | derived | — |
Growth
weight 30.83% · no data · —| Revenue growth YoY (TTM) (0.0%)data gap | — | — |
| EPS growth YoY (TTM) (0.0%)data gap | — | — |
| Revenue acceleration (0.0%)data gap | — | — |
Profitability
weight 18.5% · no data · —| Operating margin (0.0%)data gap | — | — |
| 4Q gross-margin change (0.0%)data gap | — | — |
Balance sheet
weight 18.5% (→60.0%) · 57| Net debt / EBITDA (0.0%)data gap | — | — |
| Current ratio (60.0%) | 3.05 | 57 |
| Interest coverage (0.0%)data gap | — | — |
Cash flow
weight 12.33% (→40.0%) · 44| FCF margin (20.0%) | 12.5% | 50 |
| FCF yield (20.0%) | 1.5% | 38 |
Valuation
weight 12.33% · no data · —| P/E (inverted) (0.0%)data gap | — | — |
| EV/Sales (inverted) (0.0%)data gap | — | — |
Technicals (EOD)
| RSI(14) | 46.9 |
| EMA 9 / 21 | 229.79 / 234.01 |
| 200-day SMA | 294.30 |
| Volume vs 20d avg | 1.08× |
| 20-day return | -5.6% |
Exit-rule monitor
- EXITRating break: House Rating below 60
- WATCHTrend: close below 200-day average
Data source per metric (SEC XBRL tag or derivation): Revenue: RevenueFromContractWithCustomerExcludingAssessedTax · Interest expense: InterestExpenseNonoperating · D&A: DepreciationAmortizationAndAccretionNet · Market cap: SEC shares (dei EntityCommonStockSharesOutstanding (cover page)) × EOD close.
Get rating changes like ALNY's in the free Daily Brief
The market’s key events and signals, digested before the open.
- ✓ Pre-market Daily Brief: events, headlines, rating changes (2-min read)
- ✓ Sunday: Top 5 Weekly Picks, exit alerts, CSP put watchlist
- ✓ OPEX, FOMC, CPI and jobs-day reminders
Free. Want more? See Premium (waitlist).
FAQ
- What is ALNY's House Rating?
- ALNY scores 52 out of 100 (grade C) as of 2026-10-16, ranking #23 of 150 Health Care stocks we cover.
- What do analysts say about ALNY?
- We do not have enough analyst-sentiment data to score this stock.
- When does ALNY report earnings next?
- We do not have a reliable estimate for ALNY's next earnings date (irregular SEC filing history); a rough window is 2026-10-15 to 2026-11-12. Check the company's investor-relations page.
- Is ALNY a buy?
- ThetaGrade does not give personal advice. The House Rating is an educational, rules-based summary of public data; see the methodology for how it is built.
Sources: SEC EDGAR filings (fetched 2026-10-18), Finnhub recommendation trends, Massive EOD prices. Scores are sector percentiles; a factor without usable data is a data gap: it is left out and the remaining weights are renormalized (nothing is imputed). Educational only. Methodology